Medtronic Raises FY2027 Guidance Following Strong Q1 Results

Key Facts

In a move reflecting the resilience of the healthcare technology sector, Medtronic announced strong financial results for its first quarter of fiscal year 2027, which ended July 31, 2026. According to reports, the company demonstrated strength across its largest franchises and growth platforms, leading management to raise its full-year financial guidance. This optimism is supported by recent strategic investments in growth platforms and the broad-based performance of the company's diverse product portfolio.

Based on these results, the company raised its fiscal year 2027 organic revenue growth guidance to a range of 7.25% to 7.75%, up from the prior range of 6.75% to 7.25%. Additionally, the non-GAAP diluted EPS guidance was updated to a new range of $5.94 to $6.00. Per market data, these upward revisions signal company confidence in its long-term growth trajectory despite broader operational environments.

At the close of August 31, 2026, the MDT stock price stood at $90.65, having reached a day high of $91.12. Investors are monitoring current support levels near $90.04, the low reached during the last trading session. With no major upcoming corporate catalysts listed in the immediate calendar, market attention remains focused on the company's ability to execute its stated investment strategies.